GETI.B

210.9

-0.99%↓

CAMX

695

-0.14%↓

BIOAB

269.6

+0.97%↑

VITR

136.3

+1.26%↑

EKTA.B

49.54

-0.68%↓

GETI.B

210.9

-0.99%↓

CAMX

695

-0.14%↓

BIOAB

269.6

+0.97%↑

VITR

136.3

+1.26%↑

EKTA.B

49.54

-0.68%↓

GETI.B

210.9

-0.99%↓

CAMX

695

-0.14%↓

BIOAB

269.6

+0.97%↑

VITR

136.3

+1.26%↑

EKTA.B

49.54

-0.68%↓

GETI.B

210.9

-0.99%↓

CAMX

695

-0.14%↓

BIOAB

269.6

+0.97%↑

VITR

136.3

+1.26%↑

EKTA.B

49.54

-0.68%↓

GETI.B

210.9

-0.99%↓

CAMX

695

-0.14%↓

BIOAB

269.6

+0.97%↑

VITR

136.3

+1.26%↑

EKTA.B

49.54

-0.68%↓

Home・Akciju saraksts・Vivesto AB

Vivesto AB

Atvērts

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Galvenie mērījumi
By Trading Economics
Ienākumi	-1.2M -9.5M
EPS	-0.018
Darbinieki	4

Dividendes
By Dow Jones
Nākamie ieņēmumi	2025. g. 11. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	11M 141M
Iepriekšējā atvēršanas cena	0
Iepriekšējā slēgšanas cena	0

Vivesto AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. sept. 22:39 UTC

Iegādes, apvienošanās, pārņemšana

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

2025. g. 15. sept. 16:43 UTC

Galvenie tirgus virzītāji

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

2025. g. 15. sept. 16:42 UTC

Galvenie tirgus virzītāji

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

2025. g. 15. sept. 16:35 UTC

Galvenie tirgus virzītāji

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

2025. g. 15. sept. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 15. sept. 23:46 UTC

Tirgus saruna

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

2025. g. 15. sept. 23:34 UTC

Tirgus saruna

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

2025. g. 15. sept. 22:48 UTC

Tirgus saruna

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

2025. g. 15. sept. 22:12 UTC

Iegādes, apvienošanās, pārņemšana

CSL Expects Commercial Launch in 2029

2025. g. 15. sept. 22:12 UTC

Iegādes, apvienošanās, pārņemšana

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

2025. g. 15. sept. 22:11 UTC

Iegādes, apvienošanās, pārņemšana

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

2025. g. 15. sept. 22:11 UTC

Iegādes, apvienošanās, pārņemšana

CSL to Have Right to Exercise Option Based on Phase 3 Data

2025. g. 15. sept. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

2025. g. 15. sept. 21:16 UTC

Iegādes, apvienošanās, pārņemšana

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

2025. g. 15. sept. 21:16 UTC

Iegādes, apvienošanās, pārņemšana

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

2025. g. 15. sept. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Chord Energy to Buy 48,000 Net Acres in the Williston Core

2025. g. 15. sept. 21:14 UTC

Iegādes, apvienošanās, pārņemšana

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

2025. g. 15. sept. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 15. sept. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 15. sept. 19:29 UTC

Tirgus saruna

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

2025. g. 15. sept. 19:14 UTC

Tirgus saruna

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

2025. g. 15. sept. 18:16 UTC

Tirgus saruna

Gold Powers to New High -- Market Talk

2025. g. 15. sept. 18:05 UTC

Tirgus saruna

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

2025. g. 15. sept. 17:50 UTC

Iegādes, apvienošanās, pārņemšana

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

2025. g. 15. sept. 17:10 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 15. sept. 17:10 UTC

Tirgus saruna

S&P Expects Fed, BOC to Cut Rates -- Market Talk

2025. g. 15. sept. 16:52 UTC

Tirgus saruna

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

2025. g. 15. sept. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. sept. 16:20 UTC

Tirgus saruna

Peļņas

Auto & Transport Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Vivesto AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.